peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma: increase in number of shares and votes

28 Jun 2024, 07:00
Regulatory information

Lund, Sweden June 28, 2024. Hansa Biopharma AB, (“Hansa Biopharma” or the “Company”) (Nasdaq Stockholm: HNSA) today announced that Hansa’s registered share capital and number of shares and votes have increased through (i) the issue of 2,305,260 new ordinary shares resolved on 12 April 2024 and registered with the Swedish Companies Registration Office during June 2024, whereby the number of votes increased with 2,305,260 and the share capital increased with SEK 2,305,260, and (ii) conversion of all 2,362,445 issued class C shares in Hansa to a total of 2,362,445 ordinary shares, in order to deliver ordinary shares to participants in Hansa’s outstanding incentive programs and to secure social contributions arising as a result of the incentive programs.

As of today, the total number of registered shares of Hansa amounts to 67,814,241, of which all are ordinary shares. As of today, the number of votes in Hansa amounts to 67,814,241, and the registered share capital amounts to SEK 67,814,241.

This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 28, 2024 at 07:00 CEST.

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer

Stephanie Kenney, VP Global Corporate Affairs

Notes to editors

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn.

©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.